Navigation Links
Response Genetics, Inc. to Release Second Quarter Financial Results and Host Conference Call on August 14, 2012
Date:8/7/2012

LOS ANGELES, Aug. 7, 2012 /PRNewswire/ -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, will announce its second quarter financial results and give an operational update in a press release to be issued before the market opens on Tuesday, August 14, 2012. The company will host a conference call that same day at 10:00 a.m. EDT to discuss its financial results.

Conference Call DetailsTo access the conference call by phone on August 14 at 10:00 a.m. EDT, dial (800) 537-0745 or (253) 237-1142 for international participants.  A telephone replay will be available beginning approximately two hours after the call through August 21, 2012 and may be accessed by dialing (855) 859-2056 or (404) 537-3406.  The conference passcode for both the live call and replay is 18367261.

To access the live and archived webcast of the conference call, go to the Investor Relations section of the company's Web site at http://investor.responsegenetics.com.  It is advised that participants connect at least 15 minutes prior to the call to allow for any software downloads that might be necessary.

About Response Genetics, Inc.Response Genetics Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic tests for cancer. The Company's principal customers include oncologists, pathologists and hospitals. In addition to diagnostic testing services, the Company generates revenue from the sale of its analytical testing services of clinical trial specimens to the pharmaceutical industry.  The Company's headquarters is located in Los Angeles, California. For additional information, please visit www.responsegenetics.com.

Forward-Looking Statement NoticeExcept for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to continue to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into new areas such as companion diagnostics, to continue to execute on its business strategy and operations, to continue to  analyze cancer samples, and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions.  

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law. Investor Relations Contact:

Media Relations Contact:Peter Rahmer

Barry SudbeckTrout Group

Fleishman-Hillard646-378-2973

415-318-4261


'/>"/>
SOURCE Response Genetics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
2. Market response to Kallo technology
3. Response to U.S. Supreme Courts Healthcare Decision by Michael Zamagias, Chairman, TeleTracking Technologies
4. Masimo Deploys Kinaxis RapidResponse for Global Demand and Supply Balancing
5. FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet
6. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
7. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
8. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
9. Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets
10. Alexza Receives Complete Response Letter for Adasuve™ NDA
11. Press Ganey Releases Enhanced Improvement Portal with Customized Performance Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2019)... ... October 11, 2019 , ... Based on data for ... 9 percent increase in deceased organ donors over 2018. Through August 31, 7,786 deceased ... Network (OPTN) national database . At this pace, the Association of Organ Procurement ...
(Date:10/10/2019)... WESTCHESTER COUNTY, N.Y. (PRWEB) , ... October 10, ... ... 18th annual “In Celebration” Gala Cocktail Reception on Thursday, September 26, at the ... and Susan Yubas for the unwavering support of the organization and its mission. ...
(Date:10/8/2019)... ... October 09, 2019 , ... “When Seconds Count: Reports From an Emergency ... of the HEMS world through telling the real stories of the EMS flight crew. ... published author Jay A. Humphrey, an EMS helicopter pilot. He has been a pilot ...
Breaking Medicine Technology:
(Date:10/8/2019)... ... October 08, 2019 , ... What unique insights can ... state of aging and wellness in the nation? That question will be answered at ... Conference, Leadership Summit and Expo. The event will take place October 10-12, 2019, at ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... and support services for the Department of Veterans Affairs Community Care Referrals and ... its implementation of the VA’s Health Share Referral Manager (HSRM), an enterprise-wide system ...
(Date:10/8/2019)... , ... October 08, 2019 , ... Over the past ... as a standout in the sports restaurant category by providing a higher-quality product and ... new fall menu as well as a "RAISE A MUG FOR THE CAUSE" campaign ...
(Date:10/8/2019)... , ... October 08, 2019 , ... ... CardioWise, Inc. a Digital Health Awards 1st Round (Top Ten) Finalist ... Health Awards was to select companies that promote faster, better, more cost-effective healthcare ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... of $28 billion per year, are reproducible. Rigor in bioanalytical method validation is ... (by some estimates, more than half of the time) and senior scientists add ...
Breaking Medicine News(10 mins):